Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies
Page 11 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsStatus unknownNCT03302403Not applicable
- A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell MalignancyCompletedNCT03301207Phase 1
- An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT03289182
- Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With OfatumumabStatus unknownNCT03280160Phase 2
- DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic LeukemiaTerminatedNCT03265717Phase 2
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes StudyCompletedNCT03231579
- A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 AberrationsActive, not recruitingNCT03226301Phase 2
- Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 TrialsTerminatedNCT03207256Phase 2
- A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell MalignanciesStatus unknownNCT03191773Phase 1/2
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
- A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaStatus unknownNCT03166878Phase 1/2
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell TransplantationTerminatedNCT03153514Phase 2
- Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
- C-X-C Chemokine Receptor 4 in Chronic Lymphocytic LeukemiaStatus unknownNCT03150849
- Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLActive, not recruitingNCT03128879Phase 2
- Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/LymphomaStatus unknownNCT03110640Phase 1
- Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell MalignanciesWithdrawnNCT03098355Phase 1/2
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
- Haploidentical Stem Cell Transplantation Using Post-Transplant CyclophosphamideTerminatedNCT03088709Phase 2
- A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic MalignanciesActive, not recruitingNCT03085173Phase 1
- Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesCompletedNCT03076437Phase 1/2
- CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells MalignancyCompletedNCT03068416Phase 2
- Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in ArgentinaCompletedNCT03059251
- Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
- Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 TrialCompletedNCT03003546Phase 1
- Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximabWithdrawnNCT02993536
- Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
- Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
- A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell LeukemiaStatus unknownNCT02968472Phase 1
- A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaActive, not recruitingNCT02966756Phase 2
- CAR T Cells for Refractory B Cell MalignancyStatus unknownNCT02963038Phase 1/2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
- Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompletedNCT02950051Phase 3
- Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic LeukemiaCompletedNCT02948283Phase 1
- CD19-redirected Autologous Cells (CAR-CD19 T Cells)Status unknownNCT02933775Phase 1
- Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic LymphomaTerminatedNCT02928510
- Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesCompletedNCT02924402Phase 1
- A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and ComorbiditiesCompletedNCT02915224
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
- Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia PatientsStatus unknownNCT02912754Phase 1/2
- Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell LymphomasCompletedNCT02900716Phase 1
- PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and LymphomaStatus unknownNCT02892695Phase 1/2
- Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell LymphomasCompletedNCT02891590Phase 1
- Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803CompletedNCT02890758Phase 1
- Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease ProgressionCompletedNCT02863718Phase 3
- Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02851589Phase 1/2
- Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeActive, not recruitingNCT02846623Phase 2
- a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell MalignanciesStatus unknownNCT02846584Phase 2
- A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsCompletedNCT02842229
- Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic LeukemiaStatus unknownNCT02828774
- Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic LeukemiaCompletedNCT02827617
- Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL SubjectsActive, not recruitingNCT02825836Phase 1/2
- CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02819583Phase 1/2
- iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLLCompletedNCT02802943Phase 2
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedNCT02793583Phase 2/3
- Humanized CAR-T Therapy for Treatment of B Cell MalignancyStatus unknownNCT02782351Phase 1/2
- Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLCompletedNCT02758665Phase 2
- Treatment of Chronic Lymphocytic LeukemiaStatus unknownNCT02757586
- Combination of Ibrutinib and As2O3 in the Treatment of CLLStatus unknownNCT02757040Phase 3
- Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic LeukemiaActive, not recruitingNCT02756897Phase 2
- Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaWithdrawnNCT02743546Phase 1
- Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)CompletedNCT02689141Phase 2
- Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/LymphomaStatus unknownNCT02685670Phase 1/2
- Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)WithdrawnNCT02677948Phase 1/2
- A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell LeukemiaStatus unknownNCT02672501Phase 1/2
- Phase II Trial GA101 Inbrutinib B CLLCompletedNCT02666898Phase 2
- Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell TransplantWithdrawnNCT02662296Phase 2
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell LeukemiaStatus unknownNCT02644655Phase 1/2
- A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorWithdrawnNCT02640833Phase 1
- Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)TerminatedNCT02640209Early Phase 1
- Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02629809Phase 2
- Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02623920Phase 2
- A Quality Improvement Approach to the Management of Chronic Lymphocytic LeukemiaCompletedNCT02619604Not applicable
- Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT02614508Phase 1
- Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.WithdrawnNCT02611908Phase 1
- informCLL™: A Disease Registry for Patients With Chronic Lymphocytic LeukemiaCompletedNCT02582879
- Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient ProgramCompletedNCT02582320
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLLCompletedNCT02580552Phase 1
- A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)WithdrawnNCT02576275Phase 3
- Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
- A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02556892Phase 1
- Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawnNCT02556346Phase 1
- Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia PatientsCompletedNCT02553304
- Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationCompletedNCT02535286Phase 1
- CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesCompletedNCT02529813Phase 1
- Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT02520895
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT02518555Phase 2
- Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid MalignanciesStatus unknownNCT02507479Phase 2
- A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT02500407Phase 1/2
- Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic LeukemiaCompletedNCT02491398
- Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic LeukemiaCompletedNCT02461316
- Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesStatus unknownNCT02456350Phase 1
- A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell MalignanciesTerminatedNCT02454270Phase 1
- Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Approved for marketingNCT02437019
- Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsWithdrawnNCT02420938Phase 2